Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eliquis’ European Label Supports Superiority Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol and Pfizer expect to launch novel anticoagulant Eliquis within weeks in Germany and the U.K. following approval in Europe on Nov. 20. Eliquis looks well-positioned to compete in Europe with a label reflecting superiority on safety, efficacy for stroke prevention and mortality.


Related Content

Germany’s IQWiG Approves Eliquis For AF, But Restricts Its Indication
Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy
AMPLIFY-EXT Puts Eliquis In Position For A New VTE Indication
AMPLIFY-EXT Puts Eliquis In Position For A New VTE Indication
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Doubts Linger Over Whether AVERROES Gives Any Advantage To Apixaban
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts